Pneumonic Plague Protection Induced by a Monophosphoryl Lipid A Decorated <i>Yersinia</i> Outer‐Membrane‐Vesicle Vaccine
Saugata Majumder, Shreya Das, Peng Li, Nicole Yang, Hazel Dellario, Haixin Sui, Ziqiang Guan, Wei Sun
Abstract
Abstract A new Yersinia pseudotuberculosis mutant strain, YptbS46, carrying the lpxE insertion and pmrF‐J deletion is constructed and shown to exclusively produce monophosphoryl lipid A (MPLA) having adjuvant properties. Outer membrane vesicles (OMVs) isolated from YptbS46 harboring an lcrV expression plasmid, pSMV13, are designated OMV 46 ‐LcrV, which contained MPLA and high amounts of LcrV (Low Calcium response V) and displayed low activation of Toll‐like receptor 4 (TLR4). Intramuscular prime‐boost immunization with 30 µg of of OMV 46 ‐LcrV exhibited substantially reduced reactogenicity than the parent OMV 44 ‐LcrV and conferred complete protection to mice against a high‐dose of respiratory Y. pestis challenge. OMV 46 ‐LcrV immunization induced robust adaptive responses in both lung mucosal and systemic compartments and orchestrated innate immunity in the lung, which are correlated with rapid bacterial clearance and unremarkable lung damage during Y. pestis challenge. Additionally, OMV 46 ‐LcrV immunization conferred long‐term protection. Moreover, immunization with reduced doses of OMV 46 ‐LcrV exhibited further lower reactogenicity and still provided great protection against pneumonic plague. The studies strongly demonstrate the feasibility of OMV 46 ‐LcrV as a new type of plague vaccine candidate.